We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Yanda is the place where the customer can create his or own trading bot from scratch without any deposit or coding. Since 2018, the company has opened more than 9,000 accounts and, its traders are able to execute 16,000 trading bots with a success rate of more than 97 %. Yanda traders have created more than 17,000 trading strategies. Its software allows cryptocurrency traders to automate their trading strategy. Yanda makes trading cryptocurrencies simpler and less time-consuming. It has over 1000 followers on Twitter and every week it publishes market updates on its blog. Yanda believes that automated trading for the cryptocurrency is the future. Its mission is to reach out to more than 10 million cryptocurrency holders worldwide.
days to go: Expired investment: £24,380
Zentraxa is focused on precision bioengineering to produce peptides with predictable properties tailored towards purpose. The company points out that peptides are amino acids that are the building blocks of certain proteins needed by the skin, like collagen and elastin. It has come out with a synthetic biology platform, Zentide, that designs, produces and tests novel peptides. Zentraxa argues that Zentide can circumvent previously existing bio-design limits imposed by conventional peptide synthesis and produce tailor-made biomaterials for healthcare, personal care and industrial uses. Zentraxa is initially targeting healthcare with its first biomaterial, a debondable adhesive, for use in wound care. The company asserts that the material has other uses such as cosmetics and industrial applications due to its ability to bond strongly while still being easily and painlessly removable. Zentraxa will use the investment to create a portfolio of other biomaterials for licensing to global businesses in the health and industrial sectors via its Zentide platform. 
days to go: Expired investment: £1,040,000
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph